Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD1390 |
Synonyms | |
Therapy Description |
AZD1390 is a selective inhibitor of ATM that is optimized for blood-brain barrier penetration, thus may preferentially sensitize CNS tumors for radiotherapy (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104, PMID: 29938225, PMID: 31299316). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD1390 | AZD 1390|AZD-1390 | ATM Inhibitor 13 | AZD1390 is a selective inhibitor of ATM that is optimized for blood-brain barrier penetration, thus may preferentially sensitize CNS tumors for radiotherapy (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104, PMID: 29938225, PMID: 31299316). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 mutant | glioblastoma | sensitive | AZD1390 | Preclinical - Cell culture | Actionable | In a preclinical study, TP53 mutant glioblastoma cells demonstrated increased sensitivity to radiosensitization by AZD1390 treatment compared to TP53 wild-type cells in culture (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104). | detail... |
ATM positive | glioblastoma | sensitive | AZD1390 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, AZD1390 inhibited Atm activity, sensitized glioblastoma cell lines to radiotherapy in culture, and demonstrated efficacy in mouse models of glioblastoma (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104). | detail... |
ATM positive | lung cancer | sensitive | AZD1390 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, AZD1390 inhibited Atm activity, sensitized lung cancer cells to radiotherapy in culture, and demonstrated efficacy in cell line xenograft models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05116254 | Phase I | AZD1390 + Durvalumab AZD1390 | Sarcomas and DDR-Inhibition; a Combined Modality Study (SADDRIN-1) | Recruiting | NLD | 0 |
NCT05182905 | Phase I | AZD1390 | Phase 0 Plus Expansion Study of AZD1390 in Recurrent GBM Patients | Recruiting | USA | 0 |
NCT03423628 | Phase I | AZD1390 | A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer | Recruiting | USA | GBR | 1 |
NCT05678010 | Phase I | AZD1390 | A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer | Recruiting | USA | 0 |
NCT04550104 | Phase I | AZD1390 Olaparib | A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC (CONCORDE) | Recruiting | GBR | 0 |